New Treatments & Clinical Trials for Dermatomyositis

Dermatomyositis is a rare autoimmune inflammatory muscle disease characterized by muscle weakness and distinctive skin findings including a heliotrope rash around the eyes and Gottron's papules over the knuckles. It can affect the lungs, heart, and swallowing, and a subset of cases are associated with underlying malignancy. Juvenile dermatomyositis is a distinct form affecting children, generally with a better prognosis.

What's actually going on in research

Corticosteroids remain the initial treatment, supplemented by methotrexate, azathioprine, or mycophenolate for steroid-sparing. Intravenous immunoglobulin (IVIG) is now recognized as effective for muscle disease after a large trial confirmed benefit. Anti-TNF therapy has shown limited benefit but biologic research continues, with JAK inhibitors showing notable promise for both muscle and skin manifestations. Trials are also targeting specific myositis-associated autoantibodies to guide subtype-specific therapy.

What to know before you search

Eligibility requires confirmed inflammatory myopathy diagnosis, often with autoantibody profiling, and evidence of active muscle or skin disease.

What types of trials are currently open

• JAK inhibitor trials — Testing tofacitinib, ruxolitinib, and baricitinib for skin and muscle disease in dermatomyositis.
• Anti-interferon trials — Evaluating monoclonal antibodies blocking the type I interferon pathway driving dermatomyositis inflammation.
• Refractory disease trials — Studying rituximab, belimumab, and novel biologics in patients failing standard immunosuppression.
• Interstitial lung disease trials — Targeting anti-MDA5-associated rapidly progressive ILD with aggressive immunosuppression strategies.
• Juvenile dermatomyositis trials — Evaluating biologic and steroid-sparing therapies specifically in pediatric dermatomyositis populations.